GGrantIndex
← Leaderboards

David E Olson

University Of California At Davis

$5,171,634
Attributed
$5,171,634
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.1M · FY201825
$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,171,634 · 3

By mechanism

R01$3,963,375 · 2
R35$1,208,259 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of California At Davis

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Property

Research focus

PropertyAutopsyScaffoldSynapsesMental DepressionStructureNeuronsPlayStructure-Activity RelationshipSafetyDendritic SpinesAnimal ModelNeuropsychiatric DisorderSmall MoleculeNeuronal PlasticityFunctional DisorderHallucinogensHuman ImagingPrefrontal CortexAtrophicAnalogPost-Traumatic Stress DisordersPharmaceutical PreparationsIboga

Grant awards (16)

High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating Addiction$541,161
R01 · FY2025 · DA · contact PI
Chemical and Molecular Tools for Modulating GPCR Function$316,440
R35 · FY2025 · GM · contact PI
High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating Addiction$540,503
R01 · FY2024 · DA · contact PI
Chemical and Molecular Tools for Modulating GPCR Function$316,281
R35 · FY2024 · GM · contact PI
Supplement: Chemical and Molecular Tools for Modulating GPCR Function$199,971
R35 · FY2024 · GM · contact PI
High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating Addiction$538,861
R01 · FY2023 · DA · contact PI
Chemical and Molecular Tools for Modulating GPCR Function$375,567
R35 · FY2023 · GM · contact PI
High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating Addiction$552,154
R01 · FY2022 · DA · contact PI
Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids$278,056
R01 · FY2022 · GM · contact PI
Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids$118,342
R01 · FY2022 · GM · contact PI
Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids$281,324
R01 · FY2021 · GM · contact PI
Administrative supplement: Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids$118,342
R01 · FY2021 · GM · contact PI
Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids$284,294
R01 · FY2020 · GM · contact PI
Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids$286,995
R01 · FY2019 · GM · contact PI
Administrative Supplement to Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids$133,893
R01 · FY2019 · GM · contact PI
Design, Synthesis, and Evaluation of Neural Plasticity-Promoting Analogs of Iboga and Ergoline Alkaloids$289,450
R01 · FY2018 · GM · contact PI